Aaron W. Abrams

Aaron W. Abrams

Auto-generated profile, based on publicly available information

Aaron W. Abrams

Cleveland Clinic, OH

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2024 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
AVAkash Virupakshaiah
Akash Virupakshaiah
VSVinicius A Schoeps
Vinicius A Schoeps
JRJonathan Race
Jonathan Race
MWMichael Waltz
Michael Waltz
SSSiefaddeen Sharayah
Siefaddeen Sharayah
EWEmmanuelle Waubant
Emmanuelle Waubant
Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently described demyelinating disorder, and children represent about 50% of all cases. Almost half of the patients experience relapses, but very few studies have evaluated predictors of relapse risk, challenging clinical management. The study aimed to identify predictors at MOGAD onset that are associated with a relapsing course. Methods Prospectively collected data from paediatric patients with MOGAD seen by the US Network of Paediatric MS Centres were leveraged. Univariable and adjusted multivariable models were used to predict recurrent disease. Results We identified 326 MOGAD cases (mean age at first event 8.9 years [SD 4.3], 57% female, 77% white and 74% non-Hispanic) and 46% relapsed during a mean follow-up of 3.9 years (SD 4.1). In the adjusted multivariable model, female sex (HR 1.66, 95% CI 1.17 to 2.36, p=0.004) and Hispanic/Latino ethnicity (HR 1.77, 95% CI 1.19 to 2.64, p=0.005) were associated with a higher risk of relapsing MOGAD. Maintenance treatment initiated before a second event with rituximab (HR 0.25, 95% CI 0.07 to 0.92, p=0.037) or intravenous immunoglobulin (IVIG) (HR 0.35, 95% CI 0.14 to 0.88, p=0.026) was associated with lower risk of a second event in multivariable analyses. Conversely, maintenance steroids were associated with a higher estimated relapse risk (HR 1.76, 95% CI 0.90 to 3.45, p=0.097). Conclusion Sex and ethnicity are associated with relapsing MOGAD. Use of rituximab or IVIG therapy shortly after onset is associated with a lower risk of the second event. Preventive treatment after a first event could be considered for those with a higher relapse risk.

24 June 2025 in Neurology
Verified
Journal Article
Closed access
CGChristopher Goyne
Christopher Goyne
AFAshley E. Fair
Ashley E. Fair
DYDefne Yilmaz
Defne Yilmaz
JRJonathan Race
Jonathan Race
ASAllison Schuette
Allison Schuette
ACAs The Us Network Of Pediatric Ms Centers
As The Us Network Of Pediatric Ms Centers
Older chronological age is associated with decreased multiple sclerosis (MS) relapse rates and increased risk of progressive disease. Measurement of biological age may be more precise than birthdate in understanding these aging effects. In addition to normal aging, MS-related accelerated aging may contribute. Measurement of biological age in adults may be confounded by the effects of natural aging and age-related comorbidities. Examining age extremes can be informative, and demonstrating accelerated biological aging in children would support a hypothesis of MS driving premature aging. We sought to compare epigenetic age in participants with pediatric-onset MS (POMS) and age-similar controls. We performed a multicenter case-control analysis of epigenetic age in a prospectively collected set of whole blood DNA samples and clinical data. Quantitative methylation scores were derived for approximately 850,000 cytosine-phosphate-guanine (CpG) sites. Epigenetic age was calculated based on 4 established epigenetic clock algorithms. Epigenetic age and age acceleration residual (AAR) were compared between participants with POMS and age-similar controls using multivariate regression analysis, adjusted for demographic variables. Epigenetic age and AAR were greater in cases (n = 125, mean age 15.7 years [SD = 2.6], 63.2% female) compared with controls (n = 145, mean age 15.3 years [SD = 3.4], 63.5% female) after adjusting for age, sex, body mass index, tobacco exposure, and socioeconomic status. This difference was statistically significant for 2 of the 4 epigenetic clocks used (Horvath β = 0.31 years [CI = -0.32-0.94], p = 0.33; Hannum β = 1.50 years [CI = 0.58-2.42], p = 0.002; GrimAge β = 0.33 years [CI = -0.30-0.96], p = 0.29; PhenoAge β = 1.72 years [CI = 0.09-3.35], p = 0.004). We observed greater point estimates of epigenetic age in participants with POMS compared with healthy controls in all epigenetic clocks tested. This difference was statistically significant for the Hannum and PhenoAge clocks after multivariable modeling. These results are consistent with those of studies in adult MS and suggest that accelerated aging may be present even in the youngest people living with MS.

18 July 2016 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ASAviv Segev
Aviv Segev
MRMitchell Rovner
Mitchell Rovner
DADavid Ian Appel
David Ian Appel
AAAaron W Abrams
Aaron W Abrams
MRMichal Rotem
Michal Rotem
YBYuval Bloch
Yuval Bloch
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

12 September 2024 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
VSVinicius A Schoeps
Vinicius A Schoeps
PBPavan Bhargava
Pavan Bhargava
AVAkash Virupakshaiah
Akash Virupakshaiah
DLDimitrios Christos Ladakis
Dimitrios Christos Ladakis
CMCarson Moseley
Carson Moseley
EWEmmanuelle Waubant
Emmanuelle Waubant
Background Lipids are of particular interest for the study of neuroinjury and neuroinflammation as structural lipids are major components of myelin, and a variety of lipid species modulate inflammation. In this study, we performed an in-depth lipidomics analysis to identify lipids associated with injury and disease activity. Methods Plasma samples were collected from paediatric-onset multiple sclerosis (MS) cases within 4 years of disease onset from 17 sites. The lipidome was measured using untargeted and targeted mass spectrometry. For cross-sectional analyses, the agreement between multiple machine learning models was used to predict neurofilament light chain (NfL) levels. In longitudinal analyses, the association between clinical (relapse count) and imaging (MRI count with ≥1 enhancing or new T2 lesion) outcomes with each metabolite was estimated using adjusted negative binomial regression. Results At sample collection, 68% of the 435 included individuals were treatment-naive, with a median disease duration of 0.8 years (IQR 0.3–1.7). For longitudinal analyses, 381 and 335 subjects had at least 1 year of clinical and imaging follow-up, respectively. In cross-sectional analyses, NfL chain levels identified structural lipids (phosphatidylcholines and phosphatidylethanolamines) as the highest-performing predictors, including external validation. In contrast, longitudinal analyses found polyunsaturated fatty acids (PUFAs) and their derivatives to be protective from subsequent disease activity (q<0.001, multiple outcomes). Conclusion There are two categories of lipids associated with MS processes. First, structural lipids strongly associated with NfL levels may result from cell lysis secondary to acute inflammation. In contrast, PUFAs, especially ω−3, had a protective effect on subsequent disease activity.

29 May 2020 in Journal of Child Neurology
Verified
Journal Article
Closed access
PDF file
AAAaron W. Abrams
Aaron W. Abrams
JSJeetendra P. Sah
Jeetendra P. Sah
SPSteven G. Pavlakis
Steven G. Pavlakis
Objective: To analyze the available literature on papilledema in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), report the first detailed pediatric case, and explore the underlying pathophysiology. Methods: First, we conducted a comprehensive literature review of all cases of papilledema in CIDP. Next, we reviewed each case, incorporating only those including cerebrospinal fluid analysis into the results. Finally, we present our pediatric patient. Results: Our literature review yielded a total of 9 adult and no pediatric cases. Cerebrospinal fluid protein and opening pressures were elevated in all cases. They were also elevated in our pediatric case. Conclusion: Prolonged periods of active immune-mediated inflammation is likely a cause of papilledema in adult CIDP, and possibly also in our pediatric case.

10 December 2024 in Neurology
Verified
Journal Article
Closed access
EWElizabeth Victoria Wilson
Elizabeth Victoria Wilson
HMHuong D. Meeks
Huong D. Meeks
BBBradley J. Barney
Bradley J. Barney
MWMichael Waltz
Michael Waltz
KCKatia Canenguez
Katia Canenguez
ACAs The United States Network Of Pediatric Multiple Sclerosis Centers
As The United States Network Of Pediatric Multiple Sclerosis Centers
Social determinants of health (SDOH) affect patient health outcomes, but the impact on patients with pediatric-onset multiple sclerosis (POMS) has not been well studied. Study objectives were to (1) describe the frequency of adverse SDOH, (2) evaluate social hardships as a potential barrier to the initiation of disease-modifying therapy (DMT), and (3) explore the association between adverse SDOH and disease outcomes in POMS, as well as study attrition. This was a retrospective multicenter observational study conducted through the United States Network of Pediatric MS Centers database. Participants were patients diagnosed with POMS (excluding primary progressive MS). The primary outcome was time to initiation of DMT. Secondary outcomes included most recent Expanded Disability Status Scale (EDSS) score, steroid treatment for the first event, time to second event, and study attrition. Demographic variables and clinical outcomes were compared between patients with and without hardships (maternal education of high school or less, public insurance/no insurance, or single/no-income household). Multivariable regression models were used to assess the impact of social hardship on study outcomes. There were 996 total participants (69% female, mean age at symptom onset and EDSS score [±SD] were 14.2 ± 3 and 1.2 ± 1.1, respectively). Of 768 patients with complete demographic information, 66% reported a hardship. Hardship was associated with younger age at symptom onset and diagnosis. While there was no difference in time to DMT initiation, patients with hardship were more likely to receive steroids for the first event (odds ratio [OR] 1.66, 95% CI 1.21-2.26, p = 0.002). Lack of private insurance was associated with increased risk of study attrition (OR 1.85, 95% CI 1.14-3.00, p = 0.012) and higher EDSS score (β = 0.15, 95% CI 0.01, 0.28). Living in a no-income household (vs dual-income) was associated with a shorter time to second event (hazard ratio 1.33, 95% CI 1.02-1.74, p = 0.034). The experience of hardships is common and associated with younger age at symptom onset and diagnosis, as well as shorter time to second event. Lack of private insurance is associated with study attrition and a higher EDSS score despite no difference in time to initiating DMT. There may be differences in early disease pathophysiology related to social hardship, and future studies are needed to better understand this complex relationship.